+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
22 Feb 2019

Abbott, Novo Nordisk partner to provide integrated digital solution to people with diabetes using insulin

/
Posted By
/
Comments0
/

Abbott, a global healthcare leader and Novo Nordisk announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies’ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.

Integrating these two products will enable healthcare professionals, caregivers and people with diabetes to view glucose and insulin data together to help them make more informed treatment decisions and to have a more meaningful and productive conversation about health outcomes.

Abbott’s FreeStyle Libre system reads glucose levels through a sensor that can be worn on the back of the upper arm eliminating the need for routine finger pricksiv. Abbott’s FreeStyle LibreLink app enables users to capture and view their real-time glucose levels, their eight-hour glucose history, and how their glucose is currently changing on their smartphone. LibreView is a secure cloud-based diabetes management system that gives people with diabetes and healthcare professionals clear, easy-to-understand reports from major glucose monitoring devices – including the FreeStyle Libre system.

Abbott is a global healthcare leader that helps people live more fully at all stages of life.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.